ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

ACRS Aclaris Therapeutics Inc

4.01
-0.31 (-7.18%)
23 Nov 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Aclaris Therapeutics Inc NASDAQ:ACRS NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.31 -7.18% 4.01 4.01 4.06 4.44 3.84 4.28 2,988,904 00:38:04

Form SC 13G - Statement of Beneficial Ownership by Certain Investors

21/11/2024 9:51pm

Edgar (US Regulatory)


 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

SCHEDULE 13G

 

Under the Securities Exchange Act of 1934

(Amendment No. )*

 

Aclaris Therapeutics, Inc.

(Name of Issuer)

 

Common Stock, $0.00001 par value

(Title of Class of Securities)

 

00461U105

(CUSIP Number)

 

November 19, 2024

(Date of Event which Requires Filing of this Statement)

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

 

Rule 13d-1(b)

 

Rule 13d-1(c)

 

Rule 13d-1(d)

 

* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

 

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 

 

 

 

1.

NAMES OF REPORTING PERSONS

 

Vivo Opportunity Fund Holdings, L.P.

2.

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

 

(a) ☐

(b) þ

3.

SEC USE ONLY

 

 

4.

CITIZENSHIP OR PLACE OF ORGANIZATION

 

Delaware

NUMBER OF

SHARES

BENEFICIALLY

OWNED BY

EACH

REPORTING

PERSON

WITH

5.

SOLE VOTING POWER

 

7,955,160 (1)

6.

SHARED VOTING POWER

 

0

7.

SOLE DISPOSITIVE POWER

 

7,955,160 (1)

8.

SHARED DISPOSITIVE POWER

 

0

9.

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

7,955,160 (1)

10.

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES      ☐

 

 

11.

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

 

7.4% (2)

12.

TYPE OF REPORTING PERSON

 

PN

 

(1) The number represents shares of common stock, $0.00001 par value (the “Common Stock”) of Aclaris Therapeutics, Inc. (the “Issuer”) held of record by Vivo Opportunity Fund Holdings, L.P. Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P.

 

(2) Based on 106,986,497 shares of Common Stock outstanding following the closing of the Issuer’s private placement offerings, as disclosed in the Issuer’s current report on Form 8-K filed with the Securities and Exchange Commission (the “SEC”) on November 18, 2024.

 

2

 

 

1.

NAMES OF REPORTING PERSONS

 

Vivo Opportunity, LLC

2.

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

 

(a) ☐

(b) þ

3.

SEC USE ONLY

 

 

4.

CITIZENSHIP OR PLACE OF ORGANIZATION

 

Delaware

NUMBER OF

SHARES

BENEFICIALLY

OWNED BY

EACH

REPORTING

PERSON

WITH

5.

SOLE VOTING POWER

 

7,955,160 (1)

6.

SHARED VOTING POWER

 

0

7.

SOLE DISPOSITIVE POWER

 

7,955,160 (1)

8.

SHARED DISPOSITIVE POWER

 

0

9.

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

7,955,160 (1)

10.

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES      ☐

 

 

11.

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

 

7.4% (2)

12.

TYPE OF REPORTING PERSON

 

OO

 

(1) The number represents shares of Common Stock of the Issuer held of record by Vivo Opportunity Fund Holdings, L.P. Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P.

 

(2) Based on 106,986,497 shares of Common Stock outstanding following the closing of the Issuer’s private placement offerings, as disclosed in the Issuer’s current report on Form 8-K filed with the SEC on November 18, 2024.

 

3

 

 

1

NAMES OF REPORTING PERSONS

 

Vivo Asia Opportunity Fund Holdings, L.P.

2

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

 

(a) ☐

(b) þ

3

SEC USE ONLY

 

 

4

CITIZENSHIP OR PLACE OF ORGANIZATION

 

Cayman Islands

NUMBER OF

SHARES

BENEFICIALLY

OWNED BY

EACH

REPORTING

PERSON

5

SOLE VOTING POWER

 

933,728 (1)

6

SHARED VOTING POWER

 

0

7

SOLE DISPOSITIVE POWER

 

933,728 (1)

8

SHARED DISPOSITIVE POWER

 

0

9

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

933,728 (1)

10

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES      ☐

 

 

11

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

 

0.9% (2)

12

TYPE OF REPORTING PERSON

 

PN

 

(1) The number represents shares of Common Stock of the Issuer held of record by Vivo Asia Opportunity Fund Holdings, L.P.  Vivo Opportunity Cayman, LLC is the general partner of Vivo Asia Opportunity Fund Holdings, L.P.  

 

(2) Based on 106,986,497 shares of Common Stock outstanding following the closing of the Issuer’s private placement offerings, as disclosed in the Issuer’s current report on Form 8-K filed with the SEC on November 18, 2024.

 

4

 

 

1

NAMES OF REPORTING PERSONS

 

Vivo Opportunity Cayman, LLC

2

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

 

(a) ☐

(b) þ

3

SEC USE ONLY

 

 

4

CITIZENSHIP OR PLACE OF ORGANIZATION

 

Cayman Islands

NUMBER OF

SHARES

BENEFICIALLY

OWNED BY

EACH

REPORTING

PERSON

5

SOLE VOTING POWER

 

933,728 (1)

6

SHARED VOTING POWER

 

0

7

SOLE DISPOSITIVE POWER

 

933,728 (1)

8

SHARED DISPOSITIVE POWER

 

0

9

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

933,728 (1)

10

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES      ☐

 

 

11

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

 

0.9% (2)

12

TYPE OF REPORTING PERSON

 

OO

 

(1) The number represents shares of Common Stock of the Issuer held of record by Vivo Asia Opportunity Fund Holdings, L.P.  Vivo Opportunity Cayman, LLC is the general partner of Vivo Asia Opportunity Fund Holdings, L.P.  

 

(2) Based on 106,986,497 shares of Common Stock outstanding following the closing of the Issuer’s private placement offerings, as disclosed in the Issuer’s current report on Form 8-K filed with the SEC on November 18, 2024.

 

5

 

 

Item 1. (a) Name of Issuer:

 

Aclaris Therapeutics, Inc. (the “Issuer”)

 

  (b) Address of Issuer’s Principal Executive Offices:

 

701 Lee Road, Suite 103, Wayne, PA 19087

 

Item 2. (a) Name of Person Filing:

 

Vivo Opportunity Fund Holdings, L.P. and its General Partner Vivo Opportunity, LLC

 

Vivo Asia Opportunity Fund Holdings, L.P and its General Partner Vivo Opportunity Cayman, LLC

 

  (b) Address of Principal Business Office or, if None, Residence:

 

192 Lytton Avenue, Palo Alto, CA 94301

 

  (c) Citizenship:

 

Vivo Opportunity Fund Holdings, L.P. is a Delaware limited partnership.

 

Vivo Opportunity, LLC is a Delaware limited liability company.

 

Vivo Asia Opportunity Fund Holdings, L.P. is a Cayman Islands limited partnership.

 

Vivo Opportunity Cayman, LLC is a Cayman Islands limited liability company.

 

  (d) Title of Class of Securities:

 

Common Stock, $0.00001 par value

 

  (e) CUSIP Number:

 

00461U105

 

Item 3. If This Statement is Filed Pursuant to §§ 240.13d-1(b), or 240.13d-2(b) or (c), Check Whether the Person Filing is a:

 

  (a) Broker or dealer registered under Section 15 of the Act.
       
  (b) Bank as defined in Section 3(a)(6) of the Act.
       
  (c) ☐  Insurance company as defined in Section 3(a)(19) of the Act.
       
  (d) ☐  Investment company registered under Section 8 of the Investment Company Act of 1940.
       
  (e) ☐  An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
       
  (f) ☐  An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
       
  (g) ☐  A parent holding company or control person in accordance with § 240.13d-1(b)(l)(ii)(G);
       
  (h) ☐  A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act;
       
  (i) ☐  A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act;
       
  (j) ☐  A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J);
       
  (k) ☐  Group, in accordance with § 240.13d-1(b)(l)(ii)(K).

 

If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1(ii)(j), please specify the type of institution: ________________

 

Not Applicable.

 

6

 

 

Item 4. Ownership.

 

  (a) Amount Beneficially Owned:

 

Vivo Opportunity, LLC beneficially owns 7,955,160 shares of Common Stock. The securities are held of record by Vivo Opportunity Fund Holdings, L.P. Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P.

 

Vivo Opportunity Cayman, LLC beneficially owns 933,728 shares of Common Stock. The securities are held of record by Vivo Asia Opportunity Fund Holdings, L.P. Vivo Opportunity Cayman, LLC is the general partner of Vivo Asia Opportunity Fund Holdings, L.P.

 

  (b) Percent of class:

 

Vivo Opportunity Fund Holdings, L.P.: 7.4%

Vivo Opportunity, LLC: 7.4%

Vivo Asia Opportunity Fund Holdings, L.P.: 0.9%

Vivo Opportunity Cayman, LLC.: 0.9%

 

  (c) Number of shares as to which such person has:

 

  (i)

Sole power to vote or to direct the vote:  

Vivo Opportunity Fund Holdings, L.P.: 7,955,160 shares

Vivo Opportunity, LLC: 7,955,160 shares

Vivo Asia Opportunity Fund Holdings, L.P.: 933,728 shares

Vivo Opportunity Cayman, LLC: 933,728 shares

 

  (ii) Shared power to vote or to direct the vote: 0

 

  (iii)

Sole power to dispose or to direct the disposition of:

Vivo Opportunity Fund Holdings, L.P.: 7,955,160 shares

Vivo Opportunity, LLC: 7,955,160 shares

Vivo Asia Opportunity Fund Holdings, L.P.: 933,728 shares

Vivo Opportunity Cayman, LLC: 933,728 shares        

 

  (iv) Shared power to dispose of or to direct the disposition of: 0

 

Item 5. Ownership of Five Percent or Less of a Class.

 

Not applicable.

 

Item 6. Ownership of More than Five Percent on Behalf of Another Person.

 

Not Applicable.

 

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

 

Not Applicable.

 

Item 8. Identification and Classification of Members of the Group.

 

Not applicable.

 

Item 9. Notice of Dissolution of Group.

 

Not applicable.

 

Item 10. Certifications.

 

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a11.

 

7

 

 

SIGNATURE

 

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

Date: November 21, 2024

 

Vivo Opportunity Fund Holdings, L.P.

 

By: Vivo Opportunity, LLC, its General Partner

 

/s/ Kevin Dai  
Name: Kevin Dai  
Title: Managing Member  

 

Vivo Opportunity, LLC

 

/s/ Kevin Dai  
Name: Kevin Dai  

Title:

Managing Member

 

 

Vivo Asia Opportunity Fund Holdings, L.P.

 

By: Vivo Opportunity Cayman, LLC, its General Partner

 

/s/ Kevin Dai  
Name: Kevin Dai  
Title: Managing Member  

 

Vivo Opportunity Cayman, LLC

 

/s/ Kevin Dai  
Name: Kevin Dai  
Title: Managing Member  

 

8

 

 

EXHIBIT INDEX

 

Exhibit

 

99.1Joint Filing Statement

 

9

 

EXHIBIT 99.1

 

Joint Filing Agreement

 

The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him, her or it contained herein, but shall not be responsible for the completeness and accuracy of the information concerning the other entities or persons, except to the extent that he, she or it knows or has reason to believe that such information is inaccurate.

 

Date: November 21, 2024  
     
Vivo Opportunity Fund Holdings, L.P.  
     
By: Vivo Opportunity, LLC, its General Partner  
     
/s/ Kevin Dai  
Name: Kevin Dai  
Title: Managing Member  
     
Vivo Opportunity, LLC  
     
/s/ Kevin Dai  
Name: Kevin Dai  
Title: Managing Member  
     
Vivo Asia Opportunity Fund Holdings, L.P.  
     
By: Vivo Opportunity Cayman, LLC, its General Partner
     
/s/ Kevin Dai  
Name: Kevin Dai  
Title: Managing Member  
     
Vivo Opportunity Cayman, LLC  
   
/s/ Kevin Dai  
Name: Kevin Dai  
Title: Managing Member  

 

 

 

 


1 Year Aclaris Therapeutics Chart

1 Year Aclaris Therapeutics Chart

1 Month Aclaris Therapeutics Chart

1 Month Aclaris Therapeutics Chart

Your Recent History

Delayed Upgrade Clock